Brokerages predict that Caladrius Biosciences (NASDAQ:CLBS) will announce earnings per share (EPS) of ($0.82) for the current quarter, according to Zacks. Zero analysts have issued estimates for Caladrius Biosciences’ earnings. Caladrius Biosciences posted earnings per share of ($1.12) in the same quarter last year, which would suggest a positive year over year growth rate of 26.8%. The business is scheduled to report its next quarterly earnings report on Monday, May 21st.
According to Zacks, analysts expect that Caladrius Biosciences will report full-year earnings of ($3.05) per share for the current financial year, with EPS estimates ranging from ($3.36) to ($2.74). For the next year, analysts expect that the business will report earnings of ($2.10) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Caladrius Biosciences.
Caladrius Biosciences (NASDAQ:CLBS) last released its earnings results on Thursday, March 22nd. The biotechnology company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.30.
Several research firms recently commented on CLBS. HC Wainwright reissued a “buy” rating on shares of Caladrius Biosciences in a research note on Tuesday, March 6th. They noted that the move was a valuation call. Chardan Capital increased their target price on shares of Caladrius Biosciences from $6.50 to $7.00 and gave the company a “buy” rating in a research note on Friday, March 23rd. Finally, Zacks Investment Research lowered shares of Caladrius Biosciences from a “hold” rating to a “sell” rating in a research note on Friday.
An institutional investor recently raised its position in Caladrius Biosciences stock. Macquarie Group Ltd. increased its position in shares of Caladrius Biosciences (NASDAQ:CLBS) by 321.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,890 shares of the biotechnology company’s stock after acquiring an additional 22,790 shares during the quarter. Macquarie Group Ltd. owned 0.32% of Caladrius Biosciences worth $105,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 5.71% of the company’s stock.
CLBS stock traded down $0.16 on Thursday, hitting $5.15. 33,511 shares of the company’s stock traded hands, compared to its average volume of 79,363. Caladrius Biosciences has a 1-year low of $2.63 and a 1-year high of $6.35. The firm has a market cap of $48.53, a PE ratio of -2.98 and a beta of 1.16.
COPYRIGHT VIOLATION NOTICE: “Brokerages Expect Caladrius Biosciences (CLBS) to Announce -$0.82 Earnings Per Share” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/10/brokerages-expect-caladrius-biosciences-clbs-to-announce-0-82-earnings-per-share.html.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Get a free copy of the Zacks research report on Caladrius Biosciences (CLBS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.